← Back to all trials
Active Not Recruiting
NCT06606314
Specified Drug-use Surveillance of Fabhalta Capsules
Conditions: Paroxysmal Nocturnal Hemoglobinuria
Sex: All
Ages: 0 Years – 100 Years
Healthy volunteers: No
Enrollment: 132
Sponsor: Novartis Pharmaceuticals
Location: Novartis Investigative Site Handa Aichi-ken
Summary
This is a multicenter, single-arm, non-interventional study (NIS) with a central registration system and an all-case surveillance system. The observation period is 48 weeks after the start of treatment with Fabhalta.
Eligibility Criteria
Inclusion Criteria:
All patients who received Fabhalta.
·
Exclusion Criteria:
Patients receiving Fabhalta for an unapproved indication under the Clinical Trials Act or GCP.
Source: ClinicalTrials.gov (NCT06606314). StuddyBuddy aggregates publicly available trial information.
